![Amber Johns [C]](https://images.contentstack.io/v3/assets/blt324fd0a04af716e6/bltd732a16e532b93fb/64c7b64685a11c126fc61a97/100322-amber_johns_[c].jpg?fit=crop&width=178&height=208)
Amber Johns
Dr Amber Johns’ research experience has focused on establishing and coordinating the development of complex, novel, large-scale research projects. Amber has clinical experience in pathology and cytology, and has been instrumental in building the Australian Pancreatic Genome Initiative (APGI) as part of Australia’s contribution to the International Cancer Genome Consortium.
Through the APGI, Amber developed and coordinated a national pancreatic cancer biobank network, with international linkage. Amber has the unique blend of clinical, community and scientific experience, which she has successfully applied in various settings with a range of stakeholders. Her unique skill set has been pivotal in the success of not only her own local groups, but providing a platform for cancer research groups across the world to thrive, through her ability to be the link between the research team, the clinical team, and patient and community groups.
Amber has extensive experience in ethical, policy and societal issues in research and currently advises the Federal Government in relation to genomic sequencing and the return of research results.
Awards
- 2012Recipient of NSW Cancer Institute’s Inaugural Wildfire Award for Outstanding Cancer Research Group
- 2014Recipient of NSW Cancer Institute’s Wildfire Award for Highly Cited Research Publication
Selected Publications
See all publications- 2023Healthcare (Basel, Switzerland)10.3390/healthcare11030431
Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area.
- 2022Diagnosis (Berlin, Germany)10.1515/dx-2022-0115
Empowering quality data - the Gordian knot of bringing real innovation into healthcare system.
- 2022Healthcare (Basel, Switzerland)10.3390/healthcare10112125
Fighting Cancer around the World: A Framework for Action.
- 2022Nature10.1038/s41586-022-04735-9
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer.
- 2021Wellcome open research10.12688/wellcomeopenres.17233.1
Engaged genomic science produces better and fairer outcomes: an engagement framework for engaging and involving participants, patients and publics in genomics research and healthcare implementation.